If this message does not display properly, please click here to launch your browser.
|
Based on our Pharmacor Renal Cell Carcinoma advisory service, Decision Resources is offering an exclusive analyst call entitled Renal Cell Carcinoma: Will the Current Market Leader, Pfizer’s Sutent, be Challenged by the Changing Dynamics in this Crowded Market? Because this presentation will feature major updates, it is ONLY available to purchasers of this Pharmacor advisory service. Please contact us to learn how you can purchase this Pharmacor advisory service and attend the analyst call. Pfizer’s Sutent was the leading agent in the renal cell carcinoma drug market in 2009 but, following the approval of GlaxoSmithKline’s Votrient/Patorma in the United States and Europe, Sutent’s dominance will be challenged. In addition, Decision Resources forecasts the launch of two additional targeted therapies by 2014—Pfizer’s axitinib and Aveo Pharmaceuticals’ tivozanib. The launch of axitinib and tivozanib will add to the already crowded renal cell carcinoma market and will erode the market shares of both Sutent and Bayer/Onyx’s Nexavar. In the United States, France, Germany, Italy, Spain, the United Kingdom and Japan, targeted therapies will account for virtually the entire renal cell carcinoma drug market in 2019, with angiogenesis inhibitors capturing 88 percent of all market sales. The remaining sales in this space will be attributed to the mTOR inhibitors, Pfizer’s Torisel and Novartis’s Afinitor. This 15-minute analyst call, presented by Decision Resources Analyst Karen Pomeranz, M.Sc., Ph.D., will answer the following questions:
Dr. Pomeranz will conduct a live Q & A session after the presentation. Registration Renal Cell Carcinoma: Will the Current Market Leader, Pfizer’s Sutent, be Challenged by the Changing Dynamics in this Crowded Market? July 13, 2010 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris). To learn how you can purchase this Pharmacor advisory service and attend the analyst call, please contact us using the information below. In North America — Keith Rourke at 781-296-2656 or krourke@dresources.com |
|
||||
Terms of Use | Privacy Policy | Contact Us | Careers |
|||||
Karen Pomeranz, M.Sc., Ph.D., is a research analyst in the oncology department at Decision Resources. She is an expert in renal cell carcinoma, non-small-cell lung cancer, small-cell lung cancer and malignant melanoma. She has also worked with the consulting group on various oncology indications. Her previous work experience includes six years of scientific research conducted at Imperial College London and Tel-Aviv University. Dr Pomeranz holds a B.Sc. and M.Sc. from Tel-Aviv University and a Ph.D. from Imperial College London.